Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $54.7 million.

  • 4D Molecular Therapeutics' Total Non-Current Liabilities rose 783.28% to $54.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.7 million, marking a year-over-year increase of 783.28%. This contributed to the annual value of $49.4 million for FY2024, which is 5576.94% up from last year.
  • 4D Molecular Therapeutics' Total Non-Current Liabilities amounted to $54.7 million in Q3 2025, which was up 783.28% from $52.4 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Total Non-Current Liabilities' 5-year high stood at $54.7 million during Q3 2025, with a 5-year trough of $12.4 million in Q2 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $30.3 million (2022), whereas its average is $33.3 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Total Non-Current Liabilities soared by 14315.16% in 2022 and then crashed by 1205.28% in 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Total Non-Current Liabilities (Quarter) stood at $34.2 million in 2021, then fell by 11.32% to $30.3 million in 2022, then rose by 4.61% to $31.7 million in 2023, then skyrocketed by 55.77% to $49.4 million in 2024, then rose by 10.71% to $54.7 million in 2025.
  • Its Total Non-Current Liabilities stands at $54.7 million for Q3 2025, versus $52.4 million for Q2 2025 and $45.7 million for Q1 2025.